IMMUNOLOGY2026™ Conference Recordings For Attendees-Human Spleen Organoids as a Preclinical Platform for Evaluating Vaccine-Induced Antibody Responses

Human Spleen Organoids as a Preclinical Platform for Evaluating Vaccine-Induced Antibody Responses

Video Transcription

Video Summary

The speaker described using human spleen organoids as an ex vivo model to study vaccine responses, especially for antigens the donors have never seen before. The team optimized culture conditions to keep organoids viable for up to eight weeks, which was necessary because primary antibody responses take time to develop. They then stimulated the organoids with an HIV envelope protein, using a nanoparticle plus CpG adjuvant in a prime-and-boost schedule. By week eight, they detected HIV-specific B cells, mainly memory B cells and plasmablasts, suggesting a primary response likely driven through an extrafollicular pathway. They also sorted these cells and identified four B cell receptor clones, which they are now purifying and characterizing. Overall, the work shows spleen organoids may be a useful platform for testing new vaccine candidates and potentially isolating antibodies against difficult viruses like HIV.

Meta Tag

Date April 18, 2026 10:30 AM - 10:45 AM

Room 157

Session Mechanistic Insights into Determinants of Vaccine Immunogenicity

Speaker Okikiola Olajide

Track Vaccines and Immunotherapy (VAC)

Year 2026

Keywords

human spleen organoids

vaccine responses

HIV envelope protein

B cell receptor clones

extrafollicular pathway

April 18, 2026 10:30 AM - 10:45 AM

157

Mechanistic Insights into Determinants of Vaccine Immunogenicity

Okikiola Olajide

Vaccines and Immunotherapy (VAC)

2026